BazEkon - Biblioteka Główna Uniwersytetu Ekonomicznego w Krakowie

BazEkon home page

Meny główne

Wiśniewska Nina (Military Institute of Medicine, Warsaw), Paluchowska Elwira (Military Institute of Medicine, Warsaw, Poland), Owczarek Witold (Military Institute of Medicine, Warsaw, Poland), Szkultecka-Dębek Monika (Roche Polska Sp. z o.o., Warsaw, Poland), Jahnz-Różyk Karina (Military Institute of Medicine, Warsaw, Poland)
Analysis of Direct Costs of Drug-Induced Skin Reactions Treatment Considering DRG Classification in the Perspective of Medical Service Provider and Public Payer
Journal of Health Policy and Outcomes Research, 2013, nr 2, s. 70-77, bibliogr. 6 poz.
Słowa kluczowe
Finansowanie służby zdrowia, Leczenie, Wycena kosztów leczenia, Usługi medyczne, Dokumentacja medyczna
Health care financing, Medical treatment, Valuation of medical treatment, Medical services, Medical records
Background: The aim of this study is an assessment of direct costs of patients' hospitalization caused by drug-induced skin reactions in Dermatology Department of Military Institute of Medicine during the period 2002-2012 from the public payer's perspective and service provider, based on the DRG classification. Data and methods: The study was carried out in a retrospective way on a group of 164 adult patients hospitalized in Department of Dermatology between 2002 and 2012. The analysis was based on data from patients' medical records. Due to the changes in health care system settlement during the long period taken into account for resources used identification, the one-year time horizon was settled to standardize cost calculations. The costs were evaluated in the perspective of public payer and service provider based on the DRG classification. Results: It was evaluated, that patient hospitalization due to drug-induced skin reactions within specific DRGs (J38 and J39), in the perspective of the public payer costs on average 971 euro per patient (J38) and 481 euros (J39) depending on the DRG group. When analyzing the complex diagnostics and pharmacologic therapy of the same group of patients in the perspective of the hospital costs the results is 636 euro in the J38 and 558 euro in J39 group per patient. Conclusions: Within the DRG, in case of J38 group the National Health Fund bear higher treatment costs than health care service provider. Higher costs are usually connected with higher amount of diagnostic examinations in case of severe dermatologic diseases, qualified to the J39 group(original abstract)
Pełny tekst
  1. Nationwide Campaign "Drug safety". Available from:; [Accesed 15.06.2010]
  2. Skibicka I., Maciejczyk A. Safety of pharmacotherapy and report adverse drug reactions. Neurol.Neurochir.Pol. 2004; 84: 503-10
  3. Burbach GJ., Zuberbier T. Diagnosis of drug-induced skin reactions: a future role for computer-aided systems? Curr Opin Allergy Clin Immunol. 2011 Oct; 11(5): 451-6
  4. Cost account of surgical remove a cataract phacoemulsification with intraocular lens implantation, edited by Paul Nawara, ethics, in 2010-2012 head of the Group for Selected Functions Systems NHF project leader DRG. Available from:; [Acessed 07.01.2013]
  5. Report adverse drug reactions. Available from:; [Acessed 07.01.2013]
  6. Busse R., Geissler A., Quentin W., Wiley M. Diagnosis-Related Groups in Europe: Moving towards transparency, efficiency and quality in hospitals. Chapter five Swan Tan S., Serdén L., Geissler A., Ineveld M., Redekop K., Heurgren M. et al. Open University Press 2011; 59-74
Cytowane przez
Udostępnij na Facebooku Udostępnij na Twitterze Udostępnij na Google+ Udostępnij na Pinterest Udostępnij na LinkedIn Wyślij znajomemu